COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD ZincZn
HC Q study #93
Source   PDF   Share   Tweet
See all 155 studies
Late treatment study
Davido et al., Int. J. Antimicrobial Agents, 2020, doi:10.1016/j.ijantimicag.2020.106129 (Peer Reviewed)
Impact of medical care including anti-infective agents use on the prognosis of COVID-19 hospitalized patients over time
Retrospective of 132 hospitalized patients. HC Q+AZ(52)/AZ(28) significantly reduced death/ICU, HR=0.45, p=0.04. Adjusted for Charlson Comorbidity Index (including age), obesity, O2, lymphocyte count, and treatments. Mean delay from admission to treatment 0.7 days.
combined intubation/hospitalization, ↓55.0%, p=0.04
Source   PDF   Share   Tweet
See all 155 studies
Please send us corrections, updates, or comments.